OssDsign Accelerates Commercial Efforts in the US

Press Release (ePRNews.com) - Uppsala, Sweden - Jan 16, 2018 - OssDsign is active on the US neurosurgical implants market with its lead product OSSDSIGN Cranial PSI, a calcium-phosphate based implant for cranioplasty. Since March 2017, OssDsign has a commercial partnership with California-based Matador Medical Inc who acts as master distributor of OSSDSIGN Cranial in the US.

Following a successful introduction of OSSDSIGN Cranial PSI on the US market, OssDsign has now executed the second step in its plans for the US, including the establishment of a wholly owned US subsidiary and the recruitment of key personnel. The strategic recruitments include Jim Marchesi and Peter Grimwade, both with extensive careers within neurosurgical devices. Their specific roles have been created in order to support clinical activities and strengthen the OssDsign brand in prioritized regions of the US.

We are pleased to see that our efforts on our most important market are working out as planned.

Anders Lundqvist

CEO, OssDsign AB

“We are pleased to see that our efforts on our most important market are working out as planned.” Says Anders Lundqvist, CEO of OssDsign. “Our strategy to work with Matador as master distributor has provided us with an initial market presence. We are now ready to execute the second step of our plan to further strengthen our US presence and accelerate our commercial efforts. The skilled and motivated team we are putting in place will work alongside Matador to increase the penetration of OSSDSIGN Cranial in key clinics in the US as well as prepare the market for future innovative product launches.”

Source : OssDsign AB
Business Info :
OssDsign

You may also like this  

DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login